Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GYKI 14451

Known as: GYKI 14,451, GYKI-14,451, GYKI-14451 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Newly developed synthetic and recombinant thrombin inhibitors possess strong anticoagulant effects. Despite these effects… Expand
Is this relevant?
1992
1992
In vitro inhibition of blood coagulation by tripeptide aldehydes--a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H.H2SO4.
A series of peptide aldehydes synthetized in our institute during the last 15 years were screened to detect their inhibitory… Expand
Is this relevant?
1990
1990
Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.
D-Phe-Pro-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent… Expand
Is this relevant?
1984
1984
GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: "in vitro" and "in vivo" studies.
The search for new compounds active in blood coagulation with different properties to classical anticoagulants, e.g. heparin, has… Expand
Is this relevant?
1982
1982
Design and synthesis of peptide inhibitors of blood coagulations.
Inhibition of blood coagulation by peptide aldehydes has been studied. Amino acid sequences were assembled from the P1-P2 portion… Expand
Is this relevant?
1981
1981
GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: activity on platelet aggregation and arachidonic acid metabolism.
Summary The in vitro effects of a new synthetic tripeptide GYK1 14,451 on platelet aggregation and arachidonic acid metabolism… Expand
Is this relevant?
1981
1981
Studies on the antithrombotic action of Boc-D-Phe-Pro-Arg-H (Gyki 14,451).
Abstract Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4… Expand
Is this relevant?
Review
1980
Review
1980
New strategies in the development of anti-atherosclerotic drugs.
The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE